Dawnrays is a Hong Kong-based pharmaceutical enterprise, established in 1995 with the main operations in China. Since July 2003, Dawnrays Pharmaceutical (Holdings) Ltd. has been listed on the Main Board of Hong Kong Stock Exchange Market with stock code HK2348. The main products of Dawnrays are API drugs and Anti-infective drugs.

Dawnrays' Active Pharmaceutical Ingredients(API)  like ceftriaxone sodium sterile, cefotaxime sodium sterile, cefoperazone sodium sterile, sulbactam sodium sterile, tazobactam sodium sterile  and Anti infectice drugs such as Rocephin(Ceftriaxone Sodium for Injection), Claforan(Cefotaxime Sodium for Injection), Magnex(Cefoperazone Sodium and Sulbactam Sodium for Injection), Cefobid( Cefoperazone Sodium) are very popular among our overseas customers.

The group is engaged in R&D, manufacturing and marketing of Cephalosporin and various specialty drugs. Supported by its advanced technology platform and integrated industrial chain, Dawnrays is in a position to supply Intermediates, APIs, and Formulations of Cephalosporin.

Dawnrays Pharma (Hong Kong) Ltd. is engaged in sales of Dawnrays products overseas. Guangdong Dawnrays Pharmaceutical Co., Ltd. has been granted GSP certificated by SFDA and have a comprehensive medicine sales network, consisting of 70 sales offices and 450 sales representatives. We engage in introducing foreign new medicines into Chinese market by exclusive, regional agency and market promotion.